CPARG.ca
  • Home • Accueil
  • Clinics • Cliniques
    • Pediatric Centres • Centres pédiatriques
    • Perinatal Centres • Centres de soins périnataux
    • Resources • Ressources
  • Research • Recherche
    • Highlights • Faits saillants
    • Collaborations
    • Publications and Results • Publications et résultats
    • Meetings • Réunions
    • News • Nouvelles
  • Surveillance • CPHSP
  • CPARG & Twitter
  • Contact us
  • CPARG (Members Only)
  • EPIC4 (Members Only)

Research  *  Recherche

The core “raison d’être” of CPARG has always been pediatric and perinatal HIV research. It originated in response to lack of information about pediatric HIV early on in the epidemic, the recognition of mother-to-child transmission of HIV, and the rapid need to develop protocols for the use of new drugs as they emerged for the prevention of mother-to-child transmission (PMTCT), and for treatment of infected children. Members of CPARG participated in the first trials of Zidovudine for PMTCT, and subsequently in studies of combination anti-retroviral therapy (cART) in children. Now twenty years later, the group continues to be active in the next phase of HIV research – investigating HIV viral remission and the potential for functional cure in children.  Seven CPARG affiliated sites are participating in the CIHR funded EPIC4 study (Early Pediatric Initiation of cART, Canadian Child Cure Cohort). In addition, there are two CPARG affiliated cohorts studying perinatal HIV transmission and the effects of HIV and cART on HIV exposed uninfected children.

2019 Highlights

Presented at the 28th Annual Canadian Conference on HIV/AIDS Research (CAHR 2019), May 9-12, 2019; Abstracts Book

2018 Highlights

Presented at the 27th Annual Canadian Conference on HIV/AIDS Research (CAHR 2018), Apr. 26-29, 2018; Abstracts Book

2017 Highlights

Presented at the 26th Annual Canadian Conference on HIV/AIDS Research (CAHR 2017), Apr. 6-9, 2017; Abstracts Book

CPHSP

Singer, J., Brophy, J., Lee, T., Bitnun, A., Kakkar, F., Alimenti, A., and Sauvé, L. (2017). Predictors of suboptimal treatment of pregnant HIV-positive women in Canada. Oral Presentation CS3.05,

Brophy, J., Lee, T., Bitnun, A., Kakkar, F., Singer, J., Alimenti, A., and Sauve, L. (2017). Is Tenofovir Use in Pregnancy Associated with Preterm Delivery? 26th Annual Canadian Conference on HIV/AIDS Research
Oral Presentation CS3.06, Montreal, QC, Canada.  

​Bitnun, A., Singer, J., Brophy, J., Lee, T., Kakkar, F., Alimenti, A., and the Canadian Perinatal HIV Surveillance Program (CPHSP). (2017).
Canadian Perinatal HIV Surveillance Program (CPHSP): Demographics, Perinatal HIV Transmission, and Treatment in Pregnancy in Canada 1997-2015.  

EPIC4 Cohort

Brophy, J., Dieumegard, H., Ransy, D., Kakkar, F., Samson, L., Hawkes, M., and the EPIC4 Study Group. (2017). Impact of Timing and Duration of Virologic Suppression on HIV Serologic and ELISpot responses in the EPIC4 cohort.

Dieumegard, H., Ransy, D., Fourati, I., Taillefer, S., Janelle-Montcalm, A., Caty, M., and the EPIC4 Study Group. (2017). Impact of sustained virologic suppression on HIV-specific cell-mediated immune responses in children and adolescents.

Hawkes, M., Brophy, J., Kakkar, F., Samson, L., Read, S., Soudeyns, H., and the EPIC4 Study Group. (2017). Residual inflammation and endothelial activation in HIV-1 vertically infected children with fully suppressed viral replication on anti-retroviral therapy.

​Kakkar, F., Brophy, J., Samson, L., Hawkes, M., Read, S., Soudeyns, H., and the EPIC4 Study Group. (2017). The Early Pediatric Initiation, Canada Child Cure Cohort Study (EPIC4): Successes and Failures of Early Combination Antiretroviral Therapy (cART) Initiation.

CARMA

CARMA on PUBMED: https://www.ncbi.nlm.nih.gov/pubmed/?term=Cote+H+CARMA

Dernière mise à jour :         /        Last updated on:
Copyright © 2023 CPARG
 Proudly powered by Weebly